Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PersonGen BioTherapeutics
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Multiple CAR-T programs in Phase 1 clinical trials, including PA3-17 (CD7-CAR-T) for T-cell malignancies with Breakthrough Therapy Designation in China and Orphan Drug Designation in US; TAA06 (B7-H3 CAR-T) for neuroblastoma with first patient dosed and FDA ODD/RPD.
- Therapeutic areas
- OncologyRheumatology
- Modalities
- CAR-T cell therapyCAR-NK cell therapyγδT cell therapyUniversal CAR-TAutologous CAR-TNanobody
- Industry
- Biotech
02
Partnerships
TransgeneAnhui Anke Biotechnology (Group) Co., Ltd.
Beyond the preview
Go deeper on PersonGen BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PersonGen BioTherapeutics.